The single most common fear first-time Botox patients describe is not pain, cost, or safety. It is the fear of looking "done" — a stiff forehead, an arched brow, a face that does not move when they laugh. This fear is reasonable, because it still happens. But it is also preventable, because the cause is almost always identifiable: too many units, wrong placement, or a provider who treats every forehead the same way.
The product has not changed. Botox Cosmetic (onabotulinumtoxinA) received its first FDA approval for glabellar lines in 2002 and picked up lateral canthal lines (crow's feet) in 2013 and forehead lines in 2017. The labeled doses — 20 units glabellar, 20 units forehead (always co-treated), 24 units crow's feet — have been stable for years. What has changed is the injection philosophy: from "maximum line reduction" toward "soften the line, keep the face moving."
This article is about how that philosophy works in practice, what goes wrong when it is ignored, and what a patient can evaluate before sitting in the chair.
The anatomy that makes or breaks a Botox result
Three muscle groups drive the upper-face expressions most patients want treated.
Frontalis. A broad, thin sheet that runs from the brow line to the hairline. It elevates the eyebrows and creates horizontal forehead lines. It is the only elevator of the brow — everything else pulls down. Overtreating frontalis means the brow drops (ptosis) or the face looks mask-like. Undertreating means lines persist. The art is hitting the zone between "still moves, lines softer."
Corrugator and procerus. The corrugators pull the brows medially and downward (the "11s"). The procerus pulls the skin between the brows down, creating a horizontal crease at the nasal bridge. These are depressors, and treating them is generally lower-risk for a frozen look because their motion is not essential to normal expression. The FDA-labeled 20-unit glabellar dose targets five injection points across these muscles.
Orbicularis oculi. The circular muscle around each eye. Squeezing it creates crow's feet. The FDA label uses six injection points (three per side) totaling 24 units. This muscle also assists eyelid closure, so misplaced injections can cause eyelid droop (ptosis) or dry eye.
A provider who treats all three areas with full label doses on every patient will produce a very smooth, very still upper face. That is exactly the result most patients no longer want.
How frozen happens
The frozen look is not mysterious. It traces to specific, avoidable decisions.
Too many units per area. The label doses are maximums, not starting points. Many providers — especially those who price per unit and work in high-volume clinics — default to or exceed label dose on every patient. A young patient with fine lines and a strong frontalis may need half the labeled 20 units in the forehead to look natural. The label explicitly states that doses should be individualized to the patient's anatomy and line patterns.
Treating the forehead without the glabella. The FDA label requires that forehead lines be treated in conjunction with glabellar lines, for a combined 40 units. The reason is anatomical: treating frontalis alone removes the brow elevator without weakening the depressors. The brows drop, the lateral brow arches unnaturally, and the patient looks startled. This is one of the most common causes of an "overdone" appearance, and it is a placement error, not a product error.
Ignoring muscle variation. Some patients have a strong, wide frontalis that creates lines across the full width of the forehead. Others have a narrow band of activity concentrated centrally. A five-point injection pattern designed for a wide forehead, applied to a narrow one, puts toxin into muscle that does not need it and weakens the lateral brow more than intended. The FDA label says injection points should be individualized based on palpation and observation of the patient's specific muscle activity.
Overdiffusion from concentrated injections. Reconstituted Botox spreads after injection. The more concentrated the solution (fewer injection points, larger volume per point), the further it diffuses. A provider who injects the full 20 forehead units at three points instead of five creates wider diffusion into adjacent muscles, increasing the chance of brow ptosis or an unnatural spread of paralysis.
The microdosing approach ("baby Botox")
The trend toward lower total doses — sometimes called "baby Botox," "micro-Botox," or "microdosing" — is not a new product. It is a dosing philosophy: use fewer units, placed more precisely, accepting partial rather than complete line reduction in exchange for preserved movement.
The approach typically uses roughly half the label dose per area, distributed across the same or slightly adjusted injection points. A patient who might receive 20 units in the forehead at full dose gets 10–12 units instead. Lines soften but do not disappear at rest. The face still moves. The tradeoff is duration: lower doses tend to wear off faster, often in 8–10 weeks rather than 12–16, which means more frequent visits and higher cumulative cost per year.
Microdosing is particularly suited to:
- Patients under 35 with fine dynamic lines that have not yet etched into static wrinkles.
- Patients who have never had neuromodulators and want to see how they respond before committing to a full dose.
- Patients whose work or social life requires visible facial animation (performers, sales, public-facing roles).
- Patients who have previously experienced a frozen result and are cautious about repeating it.
It is not well suited to patients with deep static wrinkles, strong muscle activity that has resisted lower doses, or patients who specifically want maximum line correction and accept the tradeoff in movement.
What the label actually says about dosing
The Botox Cosmetic prescribing information is specific about what "individualized" means:
- Glabellar lines: 0.1 mL (4 units) into each of five sites, 20 units total. The label notes that dosing should be adjusted for "the overall relationship between the size of the subject's forehead and the distribution of frontalis muscle activity."
- Forehead lines: 0.1 mL (4 units) into each of five sites, 20 units total, always co-treated with glabellar lines (40 units combined). Two treatment rows are identified by palpation: a superior margin roughly 1 cm above the most superior forehead crease, and a lower row midway between that margin and the brow. Injection patterns are adjusted based on where the muscle is actually active.
- Crow's feet: 0.1 mL (4 units) into each of three sites per side, 24 units total. The label notes that distribution of radial lines differs among patients and that injection points should reflect the patient's specific pattern.
- Maximum cumulative dose: 400 units in a three-month interval across all indications (medical and cosmetic combined). In pure cosmetic use, a full upper-face treatment (64 units for all three areas) is well below this ceiling.
- Minimum treatment interval: The label states safety has not been evaluated for treatments more frequent than every 90 days (three months).
The key word is "individualized." The label does not say "give every patient the maximum." It says assess anatomy, adjust patterns, and start conservatively.
Onset, duration, and why results feel different over time
Botox Cosmetic onset is typically 1–2 days, with maximum clinical effect at 1–2 weeks. Duration is approximately 3–4 months for the labeled cosmetic indications. Results are not permanent, and muscle function returns gradually as new nerve terminals sprout and re-establish signaling.
With repeated treatments, two things tend to happen:
- The muscle atrophies slightly from disuse between sessions. Many patients find they need fewer units over time to achieve the same effect because the target muscle is smaller and weaker than it was at the first session.
- Patients develop a clearer sense of their preferred outcome. Someone who starts with a conservative dose may choose to increase over time as they become comfortable with the feel of reduced movement, or they may stay at the lower dose because they prefer the natural movement.
Neither of these is a safety concern. They are the expected adaptation of a reversible treatment.
Choosing a provider for natural results
The difference between a natural result and a frozen one is not the product. It is the provider. Specific things to evaluate:
Ask about their dosing philosophy. A provider who says "I always use 20 units in the forehead" is not individualizing. A provider who says "I start low and add at two weeks if needed" is practicing conservatively. The latter approach costs you a follow-up visit but dramatically reduces the chance of overcorrection.
Ask whether they co-treat glabella and forehead. If they offer forehead-only treatment without mentioning that the label requires glabellar co-treatment, they may be skipping a step that prevents brow ptosis.
Ask whether they customize injection points. The label identifies specific points but explicitly states they should be adjusted based on the patient's anatomy. A provider who marks your face while you frown, raise your brows, and smile is doing this. A provider who goes straight to injection without assessment is not.
Ask how they handle touch-ups. A conservative approach leaves room for a touch-up at two weeks — adding units to an area that needs more. This is the standard of care in most dermatology and plastic surgery practices. A provider who maximizes dose on the first visit eliminates the possibility of a controlled touch-up.
Check credentials. Board-certified dermatologists and plastic surgeons have the deepest training in facial anatomy. Nurse practitioners and physician assistants can be excellent injectors, but should be working under the supervision of a physician who reviews treatment plans. Ask who supervises, and whether the supervising physician is on-site.
What to ask before your first session
- "How many units do you typically start with in the forehead for a first-time patient?" If the answer is always 20, that is a flag.
- "Will you treat my glabella at the same time as my forehead?" The answer should be yes, per the label.
- "Do you offer a two-week follow-up to adjust if needed?" A conservative provider will welcome this.
- "Can I see before-and-after photos of your patients who wanted natural results?" The photos should show softened lines with preserved movement.
A provider who cannot or will not discuss dose ranges, injection patterns, or their approach to movement preservation is not the right provider for a natural result — regardless of price, convenience, or availability.
Sources
- BOTOX Cosmetic (onabotulinumtoxinA) Prescribing Information. Allergan/AbbVie. FDA label accessible at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103000s5306lbl.pdf
- BOTOX Cosmetic FDA-approved indications and dosing summary: https://www.botoxcosmetichcp.com/indications/ufl-indications
- Drugs.com. "Botox Cosmetic: Uses, Dosage, Side Effects, Warnings." Medically reviewed April 2026: https://www.drugs.com/botox-cosmetic.html
- Kane MA. Classification of crow's feet patterns among Caucasian women: the key to individualizing treatment. Plast Reconstr Surg. 2003;112(suppl 5):33S-39S.
- de Almeida ART, et al. Glabellar contraction patterns: a tool to optimize botulinum toxin treatment. Dermatol Surg. 2012;38(9):1506-1515.
- American Society of Plastic Surgeons (ASPS). "Looking into the future: Plastic surgery trends for 2026": https://www.plasticsurgery.org/news/articles/looking-into-the-future-plastic-surgery-trends-for-2026
